Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: A lethal two-way street

Blood

Volumn 90, Issue 5, 1997, Pages 1952-1959

  Zeytun, Ahmet ^a   Hassuneh, Mona ^a   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a,b  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL INTERACTION; CYTOTOXIC T LYMPHOCYTE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; TUMOR; TUMOR IMMUNOLOGY;

EID: 0030884017     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.5.1952     Document Type: Article

References (27)

1. Kagi D, Ledermann B, Burki K, Zinkernagel RM: Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Ann Rev Immunol 14:207, 1996
2. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233, 1991
3. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169, 1993
4. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075, 1996
5. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274:1363, 1996
6. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand expressing tumor cells - A mechanism of immune evasion? Nat Med 2:1361, 1996
7. Kranz D, Eisen H: Resistance of cytotoxic T lymphocytes to lysis by a clone of cytotoxic T lymphocytes. Proc Natl Acad Sci USA 84:3375, 1987
8. Hammond-McKibben DM, Seth A, Nagarkatti PS, Nagarkatti M: Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone: Role of interleukin-2, cycling pattern of lytic activity and adhesion molecules. Int J Cancer 60:828, 1995
9. Seth A, Gote L, Nagarkatti M, Nagarkatti PS: T-cell-receptor-independent activation of cytolytic activity of cytotoxic T lymphocytes mediated through CD44 and gp90MEL-14. Proc Natl Acad Sci USA 88:7877, 1991
10. Hammond DM, Nagarkatti PS, Gote LR, Seth A, Hassuneh MR, Nagarkatti M: Double-negative T cells from MRL-lpr/lpr mice mediate cytolytic activity when triggered through adhesion molecules and constitutively express perform gene. J Exp Med 178:2225, 1993
11. Rouvier E, Luciani MF, Golstein P: Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 177:195, 1993
12. Nagarkatti M, Hassuneh M, Seth A, Manickasundari K, Nagarkatti PS: Constitutive activation of the interleukin 2 gene in the induction of spontaneous in vitro transformation and tumorigenicity of T cells. Proc Natl Acad Sci USA 91:7638, 1994
13. Matzinger P: The JAM test. J Immunol Methods 145:185, 1991
14. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K: Concanamycin A, a powerful tool for characterization and estimation of contribution of perform-and fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156:3678, 1996
15. Kamath AB, Xu H, Nagarkatti PS, Nagarkatti M: Evidence for the induction of apoptosis in thymocytes by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) in vivo. Toxicol Appl Pharmacol 142:367, 1997
16. + cells and demonstrate defective responsiveness when activated through the TCR. Cell Immunol 137:269, 1991
17. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P: TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 181:781, 1995
18. Glass A, Walsh CM, Lynch DH, Clark WR: Regulation of the Fas lytic pathway in cloned CTL. J Immunol 156:3638, 1996
19. Duke R, Chervenak CR, Cohen JJ: Endogenous endonuclease-induced DNA fragmentation: An early event in cell-mediated cytolysis. Proc Natl Acad Sci USA 80:6361, 1983
20. Watanabe D, Suda T, Hashimoto H, Nagata S: Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders. EMBOJ 14:12-18, 1995
21. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC: A role for CD95 ligand in preventing graft rejection. Nature 377:630, 1995
22. Lau H, Yu M, Fontana A, Stoeckert C: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273:109, 1996
23. Griffith T, Brunner T, Fletcher S, Green D, Ferguson T: Fas ligand induced apoptosis as a mechanism of immune privilege. Science 270:1189, 1995
24. Nagata S: Fas ligand and immune evasion. Nat Med 2:1306, 1996
25. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, Nagata S, Kanatani Y, Wakimoto N, Nagata N, Motoyoshi K: An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 94:379, 1996
26. Nagarkatti M, Kaplan AM: The role of suppressor T cells in BCNU-mediated rejection of a syngeneic tumor. J Immunol 135:1510, 1985
27. Nagarkatti M, Toney DM, Nagarkatti PS: Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res 49:6587, 1989